Methods of treating pulmonary fibrosis
AssigneeRage Biotech Pty Ltd
InventorsMerlin Christopher Thomas, Raelene Jane Pickering
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions, methods and kits for the treatment or prevention of a condition of the airway or lung involving fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of pulmonary fibrosis, such as idiopathic pulmonary fibrosis. In one aspect, the present invention provides method of treating or preventing a condition of the airway or lung involving fibrosis in a subject in need thereof, the method comprising administering to the subject an antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE, thereby treating or preventing a condition of the airway or lung involving fibrosis in a subject.
Claims32
A method of treating or preventing a condition of the airway or lung involving fibrosis in a subject in need thereof, the method comprising administering to the subject an antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE), thereby treating or preventing a condition of the airway or lung involving fibrosis in a subject.
A method of alleviating or ameliorating a symptom of a condition of the airway or lung involving fibrosis in a subject in need thereof, the method comprising administering to the subject in need thereof an antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE), thereby alleviating or ameliorating a symptom of a condition of the airway or lung involving fibrosis in the subject.
Use of an antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE) in the manufacture of a medicament for the treatment or prevention of a condition of the airway or lung involving fibrosis in a subject in need thereof.
A method or use according to any one of the preceding claims, wherein the AON that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE) is administered directly to the airway and/or lungs.
A method or use according to any one of the preceding claims, wherein the administration of the AON promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE) in the total respiratory tract, lower respiratory tract or upper respiratory tract.
A method or use according to any one of the preceding claims, wherein the method promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE) in the lower respiratory tract, preferably the lung.
A method or use according to any one of the preceding claims, wherein the antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE) is administered via inhalation.
A method or use according to any one of the preceding claims, wherein the antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE) is administered via intranasal administration.
A method or use according to any one of the preceding claims, wherein the condition of the airway or lung involving fibrosis is pulmonary fibrosis.
A method or use according to any one of the preceding claims, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis, familial pulmonary fibrosis, pulmonary fibrosis caused by sarcoidosis, pulmonary fibrosis caused by silicosis, pulmonary fibrosis caused by asbestosis, pulmonary fibrosis caused by coal worker's pneumoconiosis, pulmonary fibrosis caused by carbon pneumoconiosis, pulmonary fibrosis caused by hypersensitivity pneumonitides, pulmonary fibrosis caused by inhalation of inorganic dust, pulmonary fibrosis caused by an infectious agent, pulmonary fibrosis caused by inhalation of noxious gases, aerosols, chemical dusts, fumes or vapors, drug-induced interstitial lung disease.
A method or use according to any one of the preceding claims, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis.
Dependencies are inferred from the claim text.